About Shuttle Pharmaceuticals Holdings, Inc.
https://www.shuttlepharma.comShuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy.
CEO
Christopher Robert Cooper BBA, MBA
Compensation Summary
(Year 2024)
Salary $274,000
Total Compensation $274,000
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public August 31, 2022
Method of going public IPO
Full time employees 9
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-16 | Reverse | 1:25 |
| 2024-08-13 | Reverse | 1:8 |
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 2
Price To Earnings 1
Price To Book 2
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 20.59%
Total Number Of Holders 1
Showing Top 1 of 1
Market Cap $1.93 M
52w High $25.25
52w Low $1.26
P/E -0.44
Volume 70.06K
Outstanding Shares 1.07M
About Shuttle Pharmaceuticals Holdings, Inc.
https://www.shuttlepharma.comShuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.27M ▼ | $-2.35M ▲ | 0% | $-1.05 ▲ | $-2.33M ▲ |
| Q2-2025 | $0 | $3.91M ▲ | $-3.71M ▼ | 0% | $-3.29 ▼ | $-3.91M ▼ |
| Q1-2025 | $0 | $2.95M ▲ | $-3.05M ▼ | 0% | $-0.75 ▼ | $-3.04M ▼ |
| Q4-2024 | $0 | $1.78M ▼ | $-1.6M ▲ | 0% | $-0.54 ▼ | $-1.44M ▲ |
| Q3-2024 | $0 | $3.05M | $-3.78M | 0% | $-0.37 | $-3.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.09M ▼ | $3.54M ▼ | $2.15M ▲ | $1.39M ▼ |
| Q2-2025 | $4.82M ▲ | $5.5M ▲ | $1.9M ▼ | $3.61M ▲ |
| Q1-2025 | $4.51M ▲ | $5.31M ▲ | $2.02M ▲ | $3.29M ▲ |
| Q4-2024 | $1.92M ▲ | $2.51M ▲ | $1.8M ▼ | $709.15K ▲ |
| Q3-2024 | $156.66K | $673.57K | $1.99M | $-1.32M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.35M ▲ | $-2.63M ▲ | $0 | $-96.38K ▼ | $-2.72M ▼ | $-2.63M ▲ |
| Q2-2025 | $-3.71M ▼ | $-3.36M ▼ | $0 | $3.66M ▼ | $305.06K ▼ | $-3.36M ▼ |
| Q1-2025 | $-3.05M ▼ | $-2.53M ▲ | $0 | $5.12M ▲ | $2.59M ▲ | $-2.53M ▲ |
| Q4-2024 | $-1.6M ▲ | $-2.69M ▼ | $0 ▼ | $4.45M ▲ | $1.76M ▲ | $-2.69M ▼ |
| Q3-2024 | $-3.78M | $-2M | $1.66M | $-196.79K | $-538.94K | $-2M |
CEO
Christopher Robert Cooper BBA, MBA
Compensation Summary
(Year 2024)
Salary $274,000
Total Compensation $274,000
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public August 31, 2022
Method of going public IPO
Full time employees 9
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-16 | Reverse | 1:25 |
| 2024-08-13 | Reverse | 1:8 |
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 2
Price To Earnings 1
Price To Book 2
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 20.59%
Total Number Of Holders 1
Showing Top 1 of 1